Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy

Tuying Yong, Xiaoqiong Zhang, Nana Bie, Hongbo Zhang, Xuting Zhang, Fuying Li, Abdul Hakeem, Jun Hu, Lu Gan (), Hélder A. Santos () and Xiangliang Yang ()
Additional contact information
Tuying Yong: Huazhong University of Science and Technology
Xiaoqiong Zhang: Huazhong University of Science and Technology
Nana Bie: Huazhong University of Science and Technology
Hongbo Zhang: Åbo Akademi University
Xuting Zhang: Huazhong University of Science and Technology
Fuying Li: Huazhong University of Science and Technology
Abdul Hakeem: Huazhong University of Science and Technology
Jun Hu: Huazhong University of Science and Technology
Lu Gan: Huazhong University of Science and Technology
Hélder A. Santos: University of Helsinki
Xiangliang Yang: Huazhong University of Science and Technology

Nature Communications, 2019, vol. 10, issue 1, 1-16

Abstract: Abstract Developing biomimetic nanoparticles without loss of the integrity of proteins remains a major challenge in cancer chemotherapy. Here, we develop a biocompatible tumor-cell-exocytosed exosome-biomimetic porous silicon nanoparticles (PSiNPs) as drug carrier for targeted cancer chemotherapy. Exosome-sheathed doxorubicin-loaded PSiNPs (DOX@E-PSiNPs), generated by exocytosis of the endocytosed DOX-loaded PSiNPs from tumor cells, exhibit enhanced tumor accumulation, extravasation from blood vessels and penetration into deep tumor parenchyma following intravenous administration. In addition, DOX@E-PSiNPs, regardless of their origin, possess significant cellular uptake and cytotoxicity in both bulk cancer cells and cancer stem cells (CSCs). These properties endow DOX@E-PSiNPs with great in vivo enrichment in total tumor cells and side population cells with features of CSCs, resulting in anticancer activity and CSCs reduction in subcutaneous, orthotopic and metastatic tumor models. These results provide a proof-of-concept for the use of exosome-biomimetic nanoparticles exocytosed from tumor cells as a promising drug carrier for efficient cancer chemotherapy.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-11718-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11718-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-11718-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().